Zentalis Pharmaceuticals Company Leadership
| ZNTL Stock | USD 1.76 0.11 5.88% |
Zentalis Pharmaceuticals employs about 124 people. The company is managed by 18 executives with a total tenure of roughly 290 years, averaging almost 16.0 years of service per executive, having 6.89 employees per reported executive. Inspection of Zentalis Pharmaceuticals' management performance can provide insight into the company performance.
Zentalis |
Zentalis Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.2524) % which means that it has lost $0.2524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4289) %, meaning that it created substantial loss on money invested by shareholders. Zentalis Pharmaceuticals' management efficiency ratios could be used to measure how well Zentalis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Zentalis Pharmaceuticals Workforce Comparison
Zentalis Pharmaceuticals Llc is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 4,079. Zentalis Pharmaceuticals holds roughly 124 in number of employees claiming about 3% of equities under Health Care industry.
Zentalis Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zentalis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zentalis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Zentalis Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bruns Ingmar few days ago Acquisition by Bruns Ingmar of 712650 shares of Zentalis Pharmaceuticals at 3.66 subject to Rule 16b-3 | ||
Myers Scott Dunseth over a week ago Insider Trading | ||
Vincent Vultaggio over two weeks ago Disposition of tradable shares by Vincent Vultaggio of Zentalis Pharmaceuticals subject to Rule 16b-3 | ||
Bruns Ingmar over a month ago Acquisition by Bruns Ingmar of 20000 shares of Zentalis Pharmaceuticals at 2.2828 subject to Rule 16b-3 | ||
Roth Iris over three months ago Acquisition by Roth Iris of 297500 shares of Zentalis Pharmaceuticals at 18.87 subject to Rule 16b-3 | ||
Vincent Vultaggio over three months ago Disposition of 1603 shares by Vincent Vultaggio of Zentalis Pharmaceuticals at 3.18 subject to Rule 16b-3 | ||
Hausman Diana over six months ago Insider Trading | ||
Johnson David Michael over six months ago Acquisition by Johnson David Michael of 48429 shares of Zentalis Pharmaceuticals subject to Rule 16b-3 |
Zentalis Pharmaceuticals Notable Stakeholders
A Zentalis Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Zentalis Pharmaceuticals often face trade-offs trying to please all of them. Zentalis Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Zentalis Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Julie MBA | President CEO | Profile | |
| Cameron MBA | President, CoFounder | Profile | |
| Diana MD | Chief Director | Profile | |
| Vincent Vultaggio | VP Officer | Profile | |
| Kevin Bunker | CoFounder Officer | Profile | |
| Carrie MD | Chief Officer | Profile | |
| Adrian MD | Executive Development | Profile | |
| Mark Lackner | Chief Strategy | Profile | |
| Ingmar MD | Chief Officer | Profile | |
| Kimberly Freeman | Chief Officer | Profile | |
| Haibo Wang | Chief Officer | Profile | |
| Adam Levy | VP Relations | Profile | |
| Melissa MBA | CFO Treasurer | Profile | |
| Kimberly MD | CEO Director | Profile | |
| Andrea JD | General Secretary | Profile | |
| Wendy Chang | Chief Officer | Profile | |
| PharmD Rasbach | Chief Officer | Profile | |
| Meena Rao | VP Assurance | Profile |
About Zentalis Pharmaceuticals Management Performance
The success or failure of an entity such as Zentalis Pharmaceuticals often depends on how effective the management is. Zentalis Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Zentalis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Zentalis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. The company was incorporated in 2014 and is based in New York, New York. Zentalis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.
Zentalis Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Zentalis Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Zentalis Pharmaceuticals within its industry.Zentalis Pharmaceuticals Manpower Efficiency
Return on Zentalis Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.4M | |
| Net Loss Per Executive | 16.2M | |
| Working Capital Per Employee | 3.4M | |
| Working Capital Per Executive | 23.7M |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.